Answers are grounded in this paper and cite their sources.
Evaluates cardiovascular outcomes of ertugliflozin across kidney function stages in type 2 diabetes, indicating consistent efficacy across risk gradients.
cardiovascular disease ■ diabetes mellitus, type 2 ■ diabetic nephropathies ■ heart failure ■ kidney diseases ■ renal insufficiency, chronic
No takes yet. Share an insight, caveat, or question.
Cherney et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: